Broadvector $8.5m IPO to develop prostate cancer and hip repair therapies
07-Sep-2010 -
Broadvector Limited has lodged a prospectus with ASIC to raise up to $8.5 million to advance the clinical development of a new prostate cancer therapy and a second therapy that repairs the common problem of aseptic loosening of hip replacements. Each of these therapies is based upon gene-directed ...
clinical trials
implants
Netherlands
+2